Latest Tyrosine kinase inhibitors Stories
Drug resistant lung cancer cells change their behavior in ways we do not understand to evade treatment, but these events can now be recapitulated and studied in mice.
FRIMLEY, England, December 8 /PRNewswire/ -- - Nilotinib Surpassed imatinib in Key Measures of Treatment Effectiveness in the Trial, in Patients With Newly-Diagnosed Disease(1) - At 12-Months, Significantly Fewer Patients Progressed to Later Stages of the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than on imatinib 400mg Once-Daily(1) - Nilotinib was Generally Well Tolerated; Only a Small Number of Patients Discontinued Due to Adverse Events(1) -...
EAST HANOVER, N.J., Dec.
Two medications approved as treatment for drug-resistant chronic myeloid leukemia continue to provide patients with quicker, better responses as a first treatment than the existing front-line drug.
Omacetaxine launches different attack on CML that is impervious to other therapies.
NEW YORK, Dec.
SOUTH SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc.
EAST HANOVER, N.J., Oct. 20 /PRNewswire/ -- Novartis announced today that TasignaÂ® (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug GleevecÂ® (imatinib mesylate) tablets*.
UH Case Medical Center study in JCO reinforces focus on personalized treatment for patients based on ethnicity.
In new research published in the open-access, peer-reviewed scientific journal PLoS ONE, Dr Patrice Dubreuil and colleagues characterize the pharmacological profile of masitinib (AB1010), a novel tyrosine kinase inhibitor (TKI) that targets the stem cell factor (KIT), PDGFR and Lyn.
- To give a box on the ear to.